Overview

Vascular Endothelial Growth Factor (VEGF) Trap-Eye: Investigation of Efficacy and Safety in Wet Age-Related Macular Degeneration (AMD)

Status:
Completed

Trial end date:
2011-08-01

Target enrollment:

Participant gender:

Summary

This study is a phase III, double-masked, randomized, study of the efficacy and safety of VEGF Trap-Eye in patients with neovascular age-related macular degeneration. Approximately 1200 patients will be randomized in Europe, Asia, Japan, Australia and South America.

Phase:

Phase 3

Details

Lead Sponsor:

Bayer

Collaborator:

Regeneron Pharmaceuticals

Treatments:

Aflibercept
Endothelial Growth Factors
Ranibizumab